{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9"},{"groupId":"OG001","value":"89.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization until progression (any progression/death within 30 days of last dosing date, or between 30-60 days of last dosing prior to start of secondary therapy). Those who did not progress/die or who progressed/died after 60 days of last dose were censored at last on-study hematologic/cytogenetic assessment; those with progression/death 30-60 days of last dosing date and after start date of secondary therapy censored at last on-study hematologic/cytogenetic assessment prior to start of secondary therapy; those who had not received study treatment censored on date randomized.","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Participants were followed-up for at least 5 years","title":"Percentage of Participants With Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}